메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Sousa A. S. (Universidade de Coimbra Portugal) Serra J. (Tecnimede Group Pharmaceutical Development Quinta da Cerca Portugal) Estevens C. (Tecnimede Group Pharmaceutical Development Quinta da Cerca Portugal) Costa R. (Tecnimede Group Pharmaceutical Development Quinta da Cerca Portugal) Ribeiro A. J. (Universidade de Coimbra Portugal)
저널정보
한국약제학회 Journal of Pharmaceutical Investigation Journal of Pharmaceutical Investigation 제53권 제2호
발행연도
2023.3
수록면
269 - 306 (38page)
DOI
10.1007/s40005-022-00603-w

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background Oral extended release (ER) delivery systems have quickly gained increasing importance because of their ability to maintain drug levels in the blood more consistently, reducing side effects and improving patient compliance. The complexity of ER formulation leads to additional development challenges in the fulfilment of quality-related regulatory requirements. Despite their challenging properties, the potential of ER system formulation and process development can be better exploited by applying quality by design (QbD) approaches and advanced modeling techniques such as machine learning (ML). Area covered This review provides a comprehensive overview of QbD concepts applied to oral ER delivery systems, clarifying the impact of raw materials and process variables on critical quality attributes (CQAs). Moreover, data science coupled with ML algorithms is also elucidated in this article as a potential tool for predicting and optimizing ER formulation design and manufacturing processes. Expert opinion QbD, as a scientific and risk-based approach, provides a comprehensive understanding of oral ER drug delivery systems improving product quality and reducing postapproval changes. Enabling QbD with ML-driven pharmaceutical development can provide an opportunity to move toward risk mitigation for efficient ER tablet formulation and process development. However, there are some barriers to overcome in the way of adopting QbD concepts. The key issues are the lack of understanding and the gap between industries and regulatory authorities concerning the scientific principles and terms beyond QbD, which can create an obstacle during the approval process. Furthermore, it is generally believed that the resources and time invested in applying QbD tools are not cost-effective during constant and continuous improvement. Today, it is time to realize that a multidisciplinary understanding of the formulation and manufacturing process is as important as achieving the final result.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0